Methods for predicting onset of a migraine in a subject by detecting STXBP3 RNA levels
AssigneeThe Translational Genomics Research Institute
InventorMatthew Huentelman
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of creating a biomarker profile, the method comprising the steps of: obtaining a sample of biofluid from a subject, wherein the sample is stored on a sample collection apparatus; removing the sample from the sample collection apparatus; extracting nucleic acids from the sample; sequencing the extracted nucleic acids to generate sequence data; and analyzing the sequence data using a two-step analytical methodology to create the biomarker profile. The present invention is also directed to methods of determining the sex of an in utero fetus, predicting onset of a migraine in a subject, and of tracking athletic performance in a subject.
Claims18
A method of predicting onset of a migraine in a human subject, the method comprising the steps of:
- obtaining a set of samples of biofluid from the human subject collected over time intervals and stored on sample collection apparatuses, wherein the biofluid is blood and the sample collection apparatus comprises a cellulose paper on which the biofluid is placed to dry, and the cellulose paper has not been treated with any chemical stabilizers of nucleic acids;
- extracting nucleic acids from the set of samples, wherein the nucleic acids are RNA;
- sequencing the extracted nucleic acids to generate sequence data, wherein the RNA is sequenced with RNA-seq;
- and
- analyzing the sequence data to identify increases in syntaxin binding protein 3 (STXBP3), wherein an at least five times increase in expression of STXBP3 compared with a sample collected at an earlier time interval indicates onset of a migraine in the human subject.
A method of predicting onset of a migraine in a human subject, the method comprising the steps of:
- obtaining a set of samples of biofluid from the subject collected over time intervals and stored on sample collection apparatuses, wherein the biofluid is blood;
- extracting nucleic acids from the set of samples, wherein the nucleic acids are RNA;
- sequencing the extracted nucleic acids to generate sequence data, wherein the RNA is sequenced with RNA-Seq;
- analyzing the sequence data to identify changes in gene expression syntaxin binding protein 3 (STXBP3), wherein an at least five times increase in expression of STXBP3 compared to an earlier sample indicates onset of a migraine in the subject;
- and
- treating the human subject for migraine when an at least five times increase in expression of STXBP3 compared with a sample collected at an earlier time interval occurs, wherein treating the migraine comprises administering to the subject an effective amount of a non-steroidal anti-inflammatory drug (NSAID), a triptan, an ergotamine, metoclopramide, lidocaine or a combination thereof;
- wherein the sample is stored on a sample collection apparatus, the sample collection apparatus comprises cellulose paper on which the biofluid is placed to dry, and the cellulose paper has not been treated with any chemical stabilizers of nucleic acids.
Dependencies are inferred from the claim text.